Bruyaka, Olga; Zeitzmann, Hanko; Chalamon, Isabelle; … - In: Journal of Business Ethics 117 (2013) 1, pp. 45-65
In recent years, the biopharmaceutical industry has seen an increase in the development of so-called orphan drugs for the treatment of rare and neglected diseases. This increase has been spurred on by legislation in the United States, Europe, and elsewhere designed to promote orphan drug...